Doximity (DOCS) Stock Forecast, Price Target & Predictions
DOCS Stock Forecast
Doximity stock forecast is as follows: an average price target of $53.38 (represents a -7.69% downside from DOCS’s last price of $57.83) and a rating consensus of 'Buy', based on 10 wall street analysts offering a 1-year stock forecast.
DOCS Price Target
The average price target for Doximity (DOCS) is $53.38 based on 1-year price targets from 10 Wall Street analysts in the past 3 months, with a price target range of $70.00 to $41.00. This represents a potential -7.69% downside from DOCS's last price of $57.83.
DOCS Analyst Ratings
According to 10 Wall Street analysts, Doximity's rating consensus is 'Buy'. The analyst rating breakdown for DOCS stock is 0 'Strong Buy' (0.00%), 6 'Buy' (60.00%), 4 'Hold' (40.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Doximity Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 14, 2024 | Jailendra Singh | Truist Financial | $49.00 | $52.60 | -6.84% | -15.27% |
| Nov 13, 2024 | Richard Close | Canaccord Genuity | $60.00 | $35.60 | 68.54% | 3.75% |
| Nov 08, 2024 | Scott Berg | Needham | $65.00 | $57.60 | 12.85% | 12.40% |
| Nov 08, 2024 | Stan Berenshteyn | Wells Fargo | $41.00 | $42.09 | -2.59% | -29.10% |
| Nov 08, 2024 | Scott Schoenhaus | KeyBanc | $70.00 | $43.42 | 61.22% | 21.04% |
| Oct 15, 2024 | Stephanie Davis | Barclays | $52.00 | $41.96 | 23.93% | -10.08% |
| Oct 08, 2024 | Elizabeth Anderson | Evercore ISI | $45.00 | $43.22 | 4.12% | -22.19% |
| Oct 07, 2024 | Allen Lutz | Bank of America Securities | $45.00 | $43.83 | 2.67% | -22.19% |
| Aug 09, 2024 | Scott Berg | Needham | $38.00 | $25.66 | 48.09% | -34.29% |
| May 17, 2024 | Stephanie Davis | Barclays | $31.00 | $27.89 | 11.15% | -46.39% |
| May 17, 2024 | Jailendra Singh | Truist Financial | $31.00 | $23.74 | 30.58% | -46.39% |
| May 17, 2024 | Elizabeth Anderson | Evercore ISI | $29.00 | $23.74 | 22.16% | -49.85% |
| Apr 23, 2024 | Craig Hettenbach | Morgan Stanley | $25.00 | $25.01 | -0.04% | -56.77% |
| Apr 01, 2024 | Elizabeth Anderson | Evercore ISI | $30.00 | $26.41 | 13.59% | -48.12% |
| Oct 23, 2022 | Elizabeth Anderson | Evercore ISI | $28.00 | $25.02 | 11.91% | -51.58% |
| Aug 05, 2022 | Jessica Tassan | Piper Sandler | $39.00 | $40.31 | -3.25% | -32.56% |
The latest Doximity stock forecast, released on Nov 14, 2024 by Jailendra Singh from Truist Financial, set a price target of $49.00, which represents a -6.84% decrease from the stock price at the time of the forecast ($52.60), and a -15.27% decrease from DOCS last price ($57.83).
Doximity Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 8 | 14 |
| Avg Price Target | - | $53.38 | $43.64 |
| Last Closing Price | $57.83 | $57.83 | $57.83 |
| Upside/Downside | -100.00% | -7.69% | -24.54% |
In the current month, the average price target of Doximity stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Doximity's last price of $57.83. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Nov 14, 2024 | Morgan Stanley | Underweight | Equal-Weight | Upgrade |
| Nov 13, 2024 | Canaccord Genuity | Hold | Downgrade | |
| Nov 08, 2024 | Bank of America Securities | Neutral | Neutral | Hold |
| Nov 08, 2024 | KeyBanc | Overweight | Upgrade | |
| Oct 15, 2024 | Barclays | Equal-Weight | Overweight | Upgrade |
| Oct 08, 2024 | Evercore ISI | Outperform | Outperform | Hold |
| Aug 20, 2024 | Jefferies | Buy | Buy | Hold |
| Aug 09, 2024 | Morgan Stanley | Underweight | Underweight | Hold |
| Aug 09, 2024 | Barclays | Equal-Weight | Equal-Weight | Hold |
| Jul 18, 2024 | Evercore ISI | Underperform | Underperform | Hold |
| Jul 18, 2024 | Wells Fargo | Neutral | Neutral | Hold |
| Jul 18, 2024 | Wells Fargo | Market Perform | Underweight | Downgrade |
| May 17, 2024 | Evercore ISI | Perform | Perform | Hold |
| Apr 23, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Apr 02, 2024 | Leerink Partners | Underperform | Underperform | Hold |
| Apr 02, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Feb 09, 2024 | Wells Fargo | Equal-Weight | Equal-Weight | Hold |
| May 18, 2022 | Needham | Buy | Buy | Hold |
| May 18, 2022 | Jefferies | Buy | Buy | Hold |
| May 18, 2022 | Morgan Stanley | Equal-Weight | Equal-Weight | Hold |
| May 18, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Doximity's last stock rating was published by Morgan Stanley on Nov 14, 2024. The company Upgrade its DOCS rating from "Underweight" to "Equal-Weight".
Doximity Financial Forecast
Doximity Revenue Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $135.28M | $113.61M | $108.47M | $110.97M | $115.26M | $102.19M | $90.64M | $93.65M | $97.88M | $79.35M | $72.67M |
| Avg Forecast | $148.02M | $180.88M | $162.70M | $149.92M | $136.61M | $168.11M | $149.92M | $138.71M | $123.52M | $152.14M | $127.13M | $119.88M | $116.41M | $127.50M | $109.05M | $107.00M | $110.09M | $111.28M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| High Forecast | $155.49M | $190.00M | $170.90M | $157.48M | $143.50M | $176.59M | $157.48M | $145.70M | $128.83M | $152.60M | $127.58M | $119.88M | $116.41M | $128.11M | $109.66M | $112.39M | $115.64M | $116.89M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| Low Forecast | $145.82M | $178.19M | $160.27M | $147.69M | $134.57M | $165.61M | $147.69M | $136.64M | $120.95M | $151.60M | $126.68M | $119.88M | $116.41M | $127.10M | $108.56M | $105.40M | $108.45M | $109.62M | $100.15M | $89.61M | $90.14M | $86.26M | $73.49M | $63.62M |
| # Analysts | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.06% | 1.04% | 1.01% | 1.01% | 1.04% | 1.02% | 1.01% | 1.04% | 1.13% | 1.08% | 1.14% |
Doximity's average Quarter revenue forecast for Mar 24 based on 4 analysts is $116.41M, with a low forecast of $116.41M, and a high forecast of $116.41M. DOCS's average Quarter revenue forecast represents a -13.95% decrease compared to the company's last Quarter revenue of $135.28M (Dec 23).
Doximity EBITDA Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $58.55M | $33.79M | $32.29M | $35.55M | $41.10M | $34.69M | $24.05M | $29.29M | $37.17M | $26.53M | $26.07M |
| Avg Forecast | $45.82M | $55.99M | $50.37M | $46.41M | $42.29M | $52.04M | $46.41M | $42.94M | $38.24M | $47.10M | $39.36M | $37.11M | $21.25M | $39.47M | $33.76M | $33.12M | $19.32M | $26.99M | $30.55M | $27.33M | $17.56M | $26.31M | $22.41M | $24.05M |
| High Forecast | $48.13M | $58.82M | $52.91M | $48.75M | $44.42M | $54.67M | $48.75M | $45.10M | $39.88M | $47.24M | $39.50M | $37.11M | $25.50M | $39.66M | $33.95M | $34.79M | $23.18M | $32.38M | $30.55M | $27.33M | $21.08M | $26.31M | $22.41M | $28.86M |
| Low Forecast | $45.14M | $55.16M | $49.62M | $45.72M | $41.66M | $51.27M | $45.72M | $42.30M | $37.44M | $46.93M | $39.22M | $37.11M | $17.00M | $39.34M | $33.61M | $32.63M | $15.46M | $21.59M | $30.55M | $27.33M | $14.05M | $26.31M | $22.41M | $19.24M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.48% | 1.00% | 0.97% | 1.84% | 1.52% | 1.14% | 0.88% | 1.67% | 1.41% | 1.18% | 1.08% |
4 analysts predict DOCS's average Quarter EBITDA for Mar 24 to be $21.25M, with a high of $25.50M and a low of $17.00M. This is -63.70% lower than Doximity's previous annual EBITDA (Dec 23) of $58.55M.
Doximity Net Income Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $47.96M | $30.60M | $28.41M | $30.67M | $33.47M | $26.30M | $22.38M | $36.73M | $55.65M | $36.09M | $26.32M |
| Avg Forecast | - | - | - | - | $55.36M | $72.86M | $63.73M | $58.46M | $46.14M | $67.71M | $51.12M | $44.73M | $26.66M | $47.76M | $33.61M | $28.64M | $24.24M | $40.40M | $29.99M | $19.95M | $22.04M | $22.21M | $17.34M | $24.28M |
| High Forecast | - | - | - | - | $58.99M | $77.64M | $67.91M | $62.29M | $56.62M | $71.82M | $51.33M | $44.74M | $32.00M | $49.75M | $37.34M | $30.52M | $29.09M | $48.48M | $29.99M | $19.95M | $26.44M | $22.21M | $17.34M | $29.14M |
| Low Forecast | - | - | - | - | $54.29M | $71.45M | $62.49M | $57.32M | $44.04M | $65.66M | $50.91M | $44.71M | $21.33M | $43.78M | $29.88M | $28.08M | $19.39M | $32.32M | $29.99M | $19.95M | $17.63M | $22.21M | $17.34M | $19.43M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 0.91% | 0.99% | 1.27% | 0.83% | 0.88% | 1.12% | 1.67% | 2.51% | 2.08% | 1.08% |
Doximity's average Quarter net income forecast for Mar 24 is $26.66M, with a range of $21.33M to $32.00M. DOCS's average Quarter net income forecast represents a -44.40% decrease compared to the company's last Quarter net income of $47.96M (Dec 23).
Doximity SG&A Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $44.60M | $39.17M | $43.70M | $42.91M | $42.73M | $37.77M | $36.86M | $36.54M | $34.78M | $29.99M | $26.57M |
| Avg Forecast | $56.15M | $68.61M | $61.72M | $56.87M | $51.82M | $63.77M | $56.87M | $52.62M | $46.86M | $57.71M | $48.23M | $45.48M | $26.53M | $48.36M | $41.37M | $40.59M | $24.12M | $25.25M | $37.99M | $33.99M | $21.93M | $32.72M | $27.88M | $24.51M |
| High Forecast | $58.98M | $72.07M | $64.83M | $59.74M | $54.43M | $66.99M | $59.74M | $55.27M | $48.87M | $57.89M | $48.40M | $45.48M | $31.84M | $48.60M | $41.60M | $42.64M | $28.94M | $30.30M | $37.99M | $33.99M | $26.31M | $32.72M | $27.88M | $29.41M |
| Low Forecast | $55.31M | $67.59M | $60.80M | $56.02M | $51.05M | $62.82M | $56.02M | $51.83M | $45.88M | $57.51M | $48.06M | $45.48M | $21.22M | $48.21M | $41.18M | $39.98M | $19.29M | $20.20M | $37.99M | $33.99M | $17.54M | $32.72M | $27.88M | $19.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.92% | 0.95% | 1.08% | 1.78% | 1.69% | 0.99% | 1.08% | 1.67% | 1.06% | 1.08% | 1.08% |
Doximity's average Quarter SG&A projection for Mar 24 is $26.53M, based on 4 Wall Street analysts, with a range of $21.22M to $31.84M. The forecast indicates a -40.51% fall compared to DOCS last annual SG&A of $44.60M (Dec 23).
Doximity EPS Forecast
| Mar 27 | Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 6 | 9 | 9 | 9 | 9 | 5 | 5 | 5 | 12 | 11 | 5 | 5 | 4 | 8 | 13 | 6 | 6 | 5 | 5 | 5 | 11 | 12 | 11 | 10 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $0.26 | $0.16 | $0.15 | $0.16 | $0.17 | $0.14 | $0.12 | $0.19 | $0.30 | $0.19 | $0.30 |
| Avg Forecast | - | - | - | - | $0.28 | $0.36 | $0.32 | $0.29 | $0.23 | $0.34 | $0.26 | $0.22 | $0.20 | $0.24 | $0.17 | $0.14 | $0.17 | $0.18 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| High Forecast | - | - | - | - | $0.29 | $0.39 | $0.34 | $0.31 | $0.28 | $0.36 | $0.26 | $0.22 | $0.20 | $0.25 | $0.19 | $0.15 | $0.18 | $0.19 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| Low Forecast | - | - | - | - | $0.27 | $0.36 | $0.31 | $0.29 | $0.22 | $0.33 | $0.25 | $0.22 | $0.20 | $0.22 | $0.15 | $0.14 | $0.17 | $0.17 | $0.15 | $0.10 | $0.15 | $0.11 | $0.09 | $0.06 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.09% | 0.95% | 1.05% | 0.93% | 0.97% | 0.93% | 1.20% | 1.29% | 2.69% | 2.18% | 4.71% |
According to 4 Wall Street analysts, Doximity's projected average Quarter EPS for Mar 24 is $0.20, with a low estimate of $0.20 and a high estimate of $0.20. This represents a -22.82% decrease compared to DOCS previous annual EPS of $0.26 (Dec 23).
Doximity Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| AMWL | American Well | $8.45 | $148.13 | 1653.02% | Hold |
| ACCD | Accolade | $3.40 | $8.08 | 137.65% | Buy |
| TXG | 10x Genomics | $14.72 | $31.75 | 115.69% | Hold |
| PGNY | Progyny | $14.74 | $22.67 | 53.80% | Hold |
| DH | Definitive Healthcare | $4.46 | $6.08 | 36.32% | Hold |
| SDGR | Schrödinger | $21.36 | $28.50 | 33.43% | Buy |
| CERT | Certara | $11.40 | $15.00 | 31.58% | Buy |
| HQY | HealthEquity | $91.09 | $108.33 | 18.93% | Buy |
| GEHC | GE HealthCare | $79.25 | $92.00 | 16.09% | Buy |
| TDOC | Teladoc Health | $10.07 | $11.00 | 9.24% | Buy |
| VEEV | Veeva Systems | $226.41 | $235.50 | 4.01% | Buy |
| DOCS | Doximity | $52.70 | $53.38 | 1.29% | Buy |